entertainment -WSS

entertainment

author：comprehensive 2025-10-01 01:00:09 - browse：53366

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Florida Supreme Court upholds state's abortion ban

leisure time

WSS

Mass General Brigham physicians react to latest merger step

Trial using CRISPR to edit HIV out of cells disappoints

Study: Black kids more likely to die after surgery than white kids

First Opinion on colorectal cancer screening: letter and response

First Opinion on colorectal cancer screening: letter and response

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

explore

entertainment

hotspot

Heart attack and stroke risk calculators need revising

Indian pharmaceutical industry in denial over drug

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Bird flu reported in person exposed to presumably infected cattle

Activists slam private health insurers over coverage restrictions

Overprescribed: High cost isn't America's only drug problem

Medicare details structure of new drug price negotiation program

Driven by the pandemic, applicants flood public health schools

What does generative AI mean for health care? We asked experts

Winning ticket for $1 billion Powerball jackpot sold in California

hotspot

Overprescribed: High cost isn't America's only drug problem

Hospitals struggle to profit from CAR

Overprescribed: High cost isn't America's only drug problem

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Gut bacteria may contribute to kidney autoimmunity, study finds

Why Congress must ban federal programs from using QALYs

leisure time

leisure time

entertainment

focus